Evolution of Distribution and Marketing Models Driven by Healthcare Digital Transformation
First written in FY2022. 5 of 7 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「• Improving operational efficiency and productivity through DX and AI / • Generating new revenue through strengthened digital marketing」
The Group is reaffirming its efforts to improve operational efficiency and productivity through healthcare DX and generate revenue through digital marketing. - FY2025AdvancedAnnual report
「• Improving operational efficiency and productivity through DX and AI / • Generating new revenue through strengthened digital marketing」
For the evolution of the distribution and marketing model in line with healthcare DX, the Group is translating into specific measures the improvement of operational efficiency through DX and AI and revenue generation through digital marketing. - FY2024-Q3RestatedAnnual report
「Under this medium-term management plan, the following were established as practical priorities, and initiatives are being undertaken to achieve them: “1. Pursuing a pharmaceutical distribution model aligned with structural changes in the market and market characteristics,” “2. Evolving the distribution and marketing model in line with advances in healthcare DX,” and “3. Advancing group management in line with the Prime Market.”」
The Group continues to pursue the evolution of the distribution and marketing model in line with advances in healthcare DX as an initiative under the Fifth Medium-Term Management Plan. - FY2024-Q2RestatedAnnual report
「Under this medium-term management plan, the following were established as practical priorities: “1. Pursuing a pharmaceutical distribution model aligned with structural changes in the market and market characteristics,” “2. Evolving the distribution and marketing model in line with advances in healthcare DX,” and “3. Advancing group management in line with the Prime Market.”」
The Group continues to pursue the evolution of the distribution and marketing model in line with advances in healthcare DX as an initiative under the Fifth Medium-Term Management Plan. - FY2024-Q1RestatedAnnual report
「Under this medium-term management plan, the following were established as practical priorities: “1. Pursuing a pharmaceutical distribution model aligned with structural changes in the market and market characteristics,” “2. Evolving the distribution and marketing model in line with advances in healthcare DX,” and “3. Advancing group management in line with the Prime Market.”」
The Group continues to pursue the evolution of the distribution and marketing model in line with advances in healthcare DX as an initiative under the Fifth Medium-Term Management Plan. - FY2023-Q1RestatedAnnual report
「As an initiative: "2. Evolving the distribution and marketing model in line with advances in healthcare DX"」
The Group is reaffirming the evolution of the distribution and marketing model in line with advances in healthcare DX as an initiative under the Fifth Medium-Term Management Plan. - FY2022First statedAnnual report
「2. Evolving the distribution and marketing model in line with advances in healthcare DX」
The Group has identified the evolution of its distribution and marketing model in response to advances in healthcare DX as a pillar of the Fifth Medium-Term Management Plan.